295 related articles for article (PubMed ID: 26022710)
1. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Khan R; Dhodapkar M; Rosenthal A; Heuck C; Papanikolaou X; Qu P; van Rhee F; Zangari M; Jethava Y; Epstein J; Yaccoby S; Hoering A; Crowley J; Petty N; Bailey C; Morgan G; Barlogie B
Haematologica; 2015 Sep; 100(9):1214-21. PubMed ID: 26022710
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
3. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.
Botta C; Di Martino MT; Ciliberto D; Cucè M; Correale P; Rossi M; Tagliaferri P; Tassone P
Blood Cancer J; 2016 Dec; 6(12):e511. PubMed ID: 27983725
[TBL] [Abstract][Full Text] [Related]
4. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Dhodapkar MV; Sexton R; Waheed S; Usmani S; Papanikolaou X; Nair B; Petty N; Shaughnessy JD; Hoering A; Crowley J; Orlowski RZ; Barlogie B
Blood; 2014 Jan; 123(1):78-85. PubMed ID: 24144643
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
6. Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
[TBL] [Abstract][Full Text] [Related]
7. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
8. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
[TBL] [Abstract][Full Text] [Related]
10. Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
[TBL] [Abstract][Full Text] [Related]
11. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.
Panero J; Stella F; Schutz N; Fantl DB; Slavutsky I
PLoS One; 2015; 10(9):e0137972. PubMed ID: 26366868
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
14. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
Kyle RA; Remstein ED; Therneau TM; Dispenzieri A; Kurtin PJ; Hodnefield JM; Larson DR; Plevak MF; Jelinek DF; Fonseca R; Melton LJ; Rajkumar SV
N Engl J Med; 2007 Jun; 356(25):2582-90. PubMed ID: 17582068
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma: present position and potential promises.
Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
17. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
18. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
19. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]